journal
https://read.qxmd.com/read/37202255/highlights-of-the-11th-international-workshop-on-waldenstrom-s-macroglobulinemia-what-we-learned-and-how-it-will-impact-scientific-discovery-and-patient-care
#1
EDITORIAL
Steven P Treon, Christopher J Patterson, Ramon Garcia Sanz, Jesus San Miguel
No abstract text is available yet for this article.
May 10, 2023: Seminars in Hematology
https://read.qxmd.com/read/37173155/report-of-consensus-panel-4-from-the-11th-international-workshop-on-waldenstrom-s-macroglobulinemia-on-diagnostic-and-response-criteria
#2
JOURNAL ARTICLE
Steven P Treon, Alessandra Tedeschi, Jesus San-Miguel, Ramon Garcia-Sanz, Kenneth C Anderson, Eva Kimby, Monique C Minnema, Giulia Benevolo, Lugui Qiu, Shuhui Yi, Evangelos Terpos, Constantine S Tam, Jorge J Castillo, Pierre Morel, Meletios Dimopoulos, Roger G Owen
Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis and response assessment. Since the initial consensus reports of the 2nd International Workshop, there have been updates in the understanding of the mutational landscape of IgM related diseases, including the discovery and prevalence of MYD88 and CXCR4 mutations; an improved recognition of disease related morbidities attributed to monoclonal IgM and tumor infiltration; and a better understanding of response assessment based on multiple, prospective trials that have evaluated diverse agents in Waldenstrom's macroglobulinemia...
April 20, 2023: Seminars in Hematology
https://read.qxmd.com/read/37099028/report-of-consensus-panel-3-from-the-11th-international-workshop-on-waldenstr%C3%A3-m-s-macroglobulinemia-recommendations-for-molecular-diagnosis-in-waldenstr%C3%A3-m-s-macroglobulinemia
#3
JOURNAL ARTICLE
Ramón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, Simone Ferrero, Stephanie Poulain, Jesus F San-Miguel, Maria L Guerrera, Daniela Drandi, Tina Bagratuni, Mary McMaster, Aldo M Roccaro, Damien Roos-Weil, Merav Leiba, Yong Li, Luigi Qiu, Jian Hou, C Fernandez De Larrea, Jorge J Castillo, M Dimopoulos, R G Owen, S P Treon, Z R Hunter
Apart from the MYD88L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring...
April 6, 2023: Seminars in Hematology
https://read.qxmd.com/read/37099032/the-epidemiology-of-waldenstr%C3%A3-m-macroglobulinemia
#4
JOURNAL ARTICLE
Mary L McMaster
Waldenström macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by the presence of lymphoplasmacytic lymphoma (LPL) in the bone marrow accompanied by a monoclonal immunoglobulin type M (IgM) in the serum. WM was first described only 80 years ago and became reportable in the US as a malignancy in 1988. Very little systematic research was conducted prior to 2000 to characterize incidence, clinical characteristics, risk factors or diagnostic and prognostic criteria, and there were essentially no WM-specific clinical interventional trials...
March 31, 2023: Seminars in Hematology
https://read.qxmd.com/read/37099030/report-of-consensus-panel-6-from-the-11-th-international-workshop-on-waldenstr%C3%A3-m-s-macroglobulinemia-on-management-of-waldenstr%C3%A3-m-s-macroglobulinemia-related-amyloidosis
#5
JOURNAL ARTICLE
Giampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, Xinxin Cao, Meletios Dimopoulos, Ramon Garcia-Sanz, Moshe E Gatt, Carlos Fernandez de Larrea, Jesus San-Miguel, Steven P Treon, Monique C Minnema
Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM...
March 29, 2023: Seminars in Hematology
https://read.qxmd.com/read/37099029/report-of-consensus-panel-5-from-the-11th-international-workshop-on-waldenstrom-s-macroglobulinemia-on-covid-19-prophylaxis-and-management
#6
JOURNAL ARTICLE
E Terpos, A R Branagan, R García-Sanz, J Trotman, L M Greenberger, D M Stephens, P Morel, E Kimby, A M Frustaci, E Hatjiharissi, J San-Miguel, M A Dimopoulos, S P Treon, V Leblond
Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom's Macroglobulinemia (WM). The key recommendations from IWWM-11 CP5 included the following: Booster vaccines for SARS-CoV-2 should be recommended to all patients with WM. Variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA...
March 29, 2023: Seminars in Hematology
https://read.qxmd.com/read/37099027/report-of-consensus-panel-1-from-the-11-th-international-workshop-on-waldenstrom-s-macroglobulinemia-on-management-of-symptomatic-treatment-na%C3%A3-ve-patients
#7
JOURNAL ARTICLE
Christian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, Ranjana Advani, Suzanne O Arulogun, Andrew R Branagan, Xinxin Cao, Shirley D'Sa, Jian Hou, Prashant Kapoor, Efstathios Kastritis, Marie J Kersten, Veronique LeBlond, Merav Leiba, Jeffrey V Matous, Jonas Paludo, Lugui Qiu, Constantine S Tam, Alessandra Tedeschi, Sheeba K Thomas, Ibrahim Tohidi-Esfahani, Marzia Varettoni, Josephine M Vos, Ramon Garcia-Sanz, Jesus San-Miguel, Meletios A Dimopoulos, Steven P Treon, Judith Trotman
Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM. The panel reiterated that watchful waiting remains the gold standard for asymptomatic patients without critically elevated IgM or compromised hematopoietic function. For first-line treatment, chemoimmunotherapy (CIT) regimens such as dexamethasone, cyclophosphamide, rituximab (DRC), or bendamustine, rituximab (Benda-R) continue to play a central role in managing WM, as they are effective, of fixed duration, generally well-tolerated, and affordable...
March 29, 2023: Seminars in Hematology
https://read.qxmd.com/read/37147252/report-of-consensus-panel-2-from-the-11th-international-workshop-on-waldenstr%C3%A3-m-s-macroglobulinemia-on-the-management-of-relapsed-or-refractory-wm-patients
#8
JOURNAL ARTICLE
S D'Sa, J V Matous, R Advani, C Buske, J J Castillo, M Gatt, P Kapoor, M J Kersten, V Leblond, M Leiba, M L Palomba, J Paludo, L Qiu, S Sarosiek, M Shadman, D Talaulikar, C S Tam, A Tedeschi, S K Thomas, I Tohidi-Esfahani, J Trotman, M Varettoni, Jmi Vos, R Garcia-Sanz, J San-Miguel, M A Dimopoulos, S P Treon, E Kastritis
The consensus panel 2 (CP2) of the 11th International Workshop on Waldenström's macroglobulinemia (IWWM-11) has reviewed and incorporated current data to update the recommendations for treatment approaches in patients with relapsed or refractory WM (RRWM). The key recommendations from IWWM-11 CP2 include: (1) Chemoimmunotherapy (CIT) and/or a covalent Bruton tyrosine kinase (cBTKi) strategies are important options; their use should reflect the prior upfront strategy and are subject to their availability...
March 27, 2023: Seminars in Hematology
https://read.qxmd.com/read/37099031/report-of-consensus-panel-7-from-the-11th-international-workshop-on-waldenstr%C3%A3-m-macroglobulinemia-on-priorities-for-novel-clinical-trials
#9
JOURNAL ARTICLE
C S Tam, P Kapoor, J J Castillo, C Buske, S M Ansell, A R Branagan, E Kimby, Y Li, M L Palomba, L Qiu, M Shadman, J P Abeykoon, S Sarosiek, Jmi Vos, S Yi, D Stephens, D Roos-Weil, A M Roccaro, P Morel, N C Munshi, K C Anderson, J San-Miguel, R Garcia-Sanz, M A Dimopoulos, S P Treon, M J Kersten
Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our knowledge of how the genomic background of WM may influence selection of therapy. Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials...
March 24, 2023: Seminars in Hematology
https://read.qxmd.com/read/37080711/infectious-complications-of-chimeric-antigen-receptor-car-t-cell-therapies
#10
REVIEW
Juan C Gea-Banacloche
CAR T-cells have revolutionized the treatment of many hematological malignancies. Thousands of patients with lymphoma, acute lymphoblastic leukemia, and multiple myeloma have received this "living medicine" and achieved durable remissions. Their place in therapy continues to evolve, and there is ongoing development of new generation CAR constructs, CAR T-cells against solid tumors and CAR T-cells against chronic infections like human immunodeficiency virus and hepatitis B. A significant fraction of CAR T-cell recipients, unfortunately, develop infections...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080710/the-natural-killer-cell-immunotherapy-platform-an-overview-of-the-landscape-of-clinical-trials-in-liquid-and-solid-tumors
#11
JOURNAL ARTICLE
Sara Piccinelli, Rizwan Romee, Roman M Shapiro
The translation of natural killer (NK) cells to the treatment of malignant disease has made significant progress in the last few decades. With a variety of available sources and improvements in both in vitro and in vivo NK cell expansion, the NK cell immunotherapy platform has come into its own. The enormous effort continues to further optimize this platform, including ways to enhance NK cell persistence, trafficking to the tumor microenvironment, and cytotoxicity. As this effort bears fruit, it is translated into a plethora of clinical trials in patients with advanced malignancies...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080709/measurable-residual-disease-after-car-t-cell-therapy
#12
REVIEW
Nora Chokr, Alexandra Gomez-Arteaga
Testing for measurable residual disease (MRD) provides important prognostic and predictive implications on survival and management of many hematologic diseases. Among the many clinical uses of MRD is post-therapy response assessment and risk stratification. With the integration of precision medicine in routine clinical care and the development of novel and innovative therapies resulting in deeper responses, it is necessary to refine the role of MRD, standardize available methodologies and define its role as a surrogate endpoint for relapse and time-to-next treatment in clinical studies...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080708/gene-editing-for-sickle-cell-disease-and-transfusion-dependent-thalassemias-a-cure-within-reach
#13
JOURNAL ARTICLE
Michael J Eckrich, Haydar Frangoul
Sickle cell disease (SCD) is associated with significant morbidity and shortened life expectancy. Similarly, patients with transfusion dependent beta thalassemia (TdT) require life-long transfusion therapy, chelation therapy and significant organ dysfunction. Allogeneic transplantation from a matched family donor provided the only curative option for patients with SCD and TdT. Unfortunately, less than 20% of patients have a fully matched related donor and results using unrelated donor transplant were associated with high rate of complications...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080707/challenges-and-opportunities-of-car-t-cell-therapies-for-cll
#14
JOURNAL ARTICLE
Ziran Zhao, Céline Grégoire, Beatriz Oliveira, Kunho Chung, Jan Joseph Melenhorst
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape of blood cancers. These engineered receptors which endow T cells with antibody-like target cell recognition combined with the typical T cell target cell lysis abilities. Introduced into the clinic in the 2010s, CAR T-cells have shown efficacy in chronic B lymphocytic leukemia (CLL), but a majority of patients do not achieve sustained remission. Here we discuss the current treatment landscape in CLL using small molecules and allogeneic stem cell transplantation, the niche CAR T-cells filled in this context, and what we have learned from biomarker and mechanistic studies...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080706/place-of-care-manufacturing-of-chimeric-antigen-receptor-cells-opportunities-and-challenges
#15
JOURNAL ARTICLE
Rimas J Orentas, Boro Dropulić, Marcos de Lima
The landscape of therapeutic options for B cell malignancies has fundamentally changed with regulatory and marketing approval of chimeric antigen receptor (CAR)-engineered T cell products. The cell types used for CAR-T production, the length of time of manufacture, the stimulation matrix, and the nature of the gene vector used to transduce human T cells all are significant variables that require adequate quality control before infusion. Having approved products available to clinicians using a centralized production paradigm has not stopped innovation in investigator-initiated trials...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080705/applications-of-virus-specific-t-cell-therapies-post-bmt
#16
REVIEW
Cecilia M Motta, Michael D Keller, Catherine M Bollard
Hematopoietic stem cell transplantation (HSCT) has been used as a curative standard of care for moderate to severe primary immunodeficiency disorders as well as relapsed hematologic malignancies for over 50 years [1,2]. However, chronic and refractory viral infections remain a leading cause of morbidity and mortality in the immune deficient period following HSCT, where use of available antiviral pharmacotherapies is limited by toxicity and emerging resistance [3]. Adoptive immunotherapy using virus-specific T cells (VSTs) has been explored for over 2 decades [4,5] in patients post-HSCT and has been shown prior phase I-II studies to be safe and effective for treatment or preventions of viral infections including cytomegalovirus, Epstein-Barr virus, BK virus, and adenovirus with minimal toxicity and low risk of graft vs host disease [6-9]...
January 2023: Seminars in Hematology
https://read.qxmd.com/read/37080704/cellular-therapies-hematology-and-beyond
#17
EDITORIAL
Sumithira Vasu
No abstract text is available yet for this article.
January 2023: Seminars in Hematology
https://read.qxmd.com/read/36805889/erratum-to-tribute-to-an-editor-neal-s-young-as-a-medical-editor-and-writer-by-omaral-ubaydli-semin-hematol-2022-59-1-4-5
#18
(no author information available yet)
No abstract text is available yet for this article.
October 2022: Seminars in Hematology
https://read.qxmd.com/read/36805888/extranodal-natural-killer-t-cell-lymphoma-an-overview-on-pathology-and-clinical-management
#19
REVIEW
Eric Tse, Christopher P Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Natural killer (NK)/T-cell lymphomas arise mainly from NK-cells and occasionally T-cells, and are universally infected with Epstein Barr virus (EBV). They are uncommon lymphomas more prevalent in Asian and Central/South American populations. NK/T-cell lymphomas are clinically aggressive and predominantly extranodal. The most commonly involved sites are the nasal cavity, followed by non-nasal sites including the skin, gastrointestinal tract and testis. The diagnosis of extranodal NK/T-cell lymphoma is established with histological and immunohistochemical examination, together with the demonstration of EBV in the tumour cells...
October 2022: Seminars in Hematology
https://read.qxmd.com/read/36805887/sars-cov-2-vaccine-induced-humoral-and-cellular-immunity-in-patients-with-hematologic-malignancies
#20
JOURNAL ARTICLE
Sabine Haggenburg, Quincy Hofsink, Caroline E Rutten, Inger S Nijhof, Mette D Hazenberg, Abraham Goorhuis
Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses...
October 2022: Seminars in Hematology
journal
journal
24399
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.